Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol “Dear Doctor” Letter: Abilify Shows No “Signal” For Diabetes

This article was originally published in The Pink Sheet Daily

Executive Summary

An “exhaustive review” of the aripiprazole database revealed “no increased signal for diabetes,” Bristol says in health care professionals letter explaining the new class warning for atypical antipsychotics.

You may also be interested in...



Bristol/Otsuka's Abilify Adds Acute Bipolar Mania Indication

FDA clears aripiprazole for the treatment of acute manic and mixed episodes associated with bipolar disorder. The approval places Abilify labeling on par with other atypical antipsychotics.

Bristol/Otsuka's Abilify Adds Acute Bipolar Mania Indication

FDA clears aripiprazole for the treatment of acute manic and mixed episodes associated with bipolar disorder. The approval places Abilify labeling on par with other atypical antipsychotics.

Geodon Labeling Changes Still Under Discussion, Pfizer Says

Pfizer is continuing to discuss new safety labeling for the antipsychotic Geodon (ziprasidone) with FDA, the company said in its April 20 earnings report

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel